Jennafer Dotson
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, Parkinson's Disease Mechanisms and Treatments, Protein Kinase Regulation and GTPase Signaling, Computational Drug Discovery Methods
Most-Cited Works
- → Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity(2013)175 cited
- → Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors(2012)161 cited
- → Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors(2013)123 cited
- → Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor(2010)88 cited
- → A Class of 2,4-Bisanilinopyrimidine Aurora A Inhibitors with Unusually High Selectivity against Aurora B(2009)81 cited
- → Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform(2011)70 cited
- → Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation(2014)61 cited
- → The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase α(2012)52 cited
- → Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR(2015)34 cited
- → Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor(2016)33 cited